| Samples | NSCLC | SCLC |
| All samples (n = 104) | ||
| Total number (%) | 82 (100) | 22 (100) |
| Squamous cell carcinoma, n (%) | 25 (31) | NA |
| Adenocarcinoma, n (%) | 35 (43) | NA |
| Mixed (squamous+adeno), n (%) | 1 (1) | NA |
| Large cell carcinoma, n (%) | 1 (1) | NA |
| NOS, n (%) | 20 (24) | NA |
| Age (years), mean (SD) | 64 (10) | 62 (11) |
| Age range (years) | 36–83 | 44–84 |
| Male, n (%) | 57 (70) | 14 (64) |
| LN negative, n (%) | 12 (15) | 0 (0) |
| Defined samples* (n = 70) | ||
| Total number (%) | 55 (100) | 15 (100) |
| Squamous cell carcinoma, n (%) | 16 (29) | NA |
| Adenocarcinoma, n (%) | 24 (44) | NA |
| NOS | 15 (27) | NA |
| Stages, n (%) | ||
| I | 5 (9) | 0 |
| II | 4 (7) | 0 |
| III | 13 (24) | 3 (20) |
| IV | 27 (49) | 11 (73) |
| Unknown | 6 (11) | 1 (7) |
| Age (years), mean (SD) | 63 (11) | 61 (10) |
| Age range (years) | 36–83 | 52–75 |
| Male, n (%) | 38 (70) | 10 (67) |
| Pretreatment samples, n (%) | 34 (62) | 13 (87) |
*Samples taken within 4 (SCLC) or 6 (NSCLC) months of diagnosis date.
LN, lymph node; NOS, not otherwise specified; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.